首页> 中文期刊> 《生物医学研究杂志(英文版)》 >A genetic variant in pseudogene E2F3P1 contributes to prognosis of hepatocellular carcinoma

A genetic variant in pseudogene E2F3P1 contributes to prognosis of hepatocellular carcinoma

         

摘要

Certain pseudogenes may regulate their protein-coding cousins by competing for miRNAs and play an active biological role in cancer.However,few studies have focused on the association of genetic variations in pseudogenes with cancer prognosis.We selected six potentially functional single nucleotide polymorphisms(SNPs) in cancerrelated pseudogenes,and performed a case-only study to assess the association between those SNPs and the prognosis of hepatocellular carcinoma(HCC) in 331 HBV-positive HCC patients without surgical treatment.Log-rank test and Cox proportional hazard models were used for survival analysis.We found that the A allele of rs9909601 in E2F3P1was significantly associated with a better prognosis compared with the G allele[adjusted hazard ratio(HR) = 0.69,95%confidence interval(CI) = 0.56-0.86,P = 0.001].Additionally,this protective effect was more predominant for patients without chemotherapy and transcatheter hepatic arterial chemoembolization(TACE) treatment.Interestingly,we also detected a statistically significant multiplicative interaction between genotypes of rs9909601 and chemotherapy or TACE status on HCC survival(P for multiplicative interaction < 0.001).These findings indicate that rs9909601 in the pseudogene E2F3P1 may be a genetic marker for HCC prognosis in Chinese.

著录项

  • 来源
    《生物医学研究杂志(英文版)》 |2014年第3期|194-200|共7页
  • 作者单位

    Department of Epidemiology and Biostatistics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;

    Department of Epidemiology and Biostatistics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;

    Department of Oncology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, China;

    pathology Center and Department of Pathology, Soochow University, Suzhou, Jiangsu 215123, China;

    Department of Hepatopancreatobiliary Surgery, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, China;

    Digestive Endoscopy Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Epidemiology and Biostatistics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号